TRCT
GALT icon

Tower Research Capital (TRC)’s Galectin Therapeutics GALT Stock Holding History

Tower Research Capital (TRC)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Buy
4,605
+195
+4% +$505 ﹤0.01% 3487
2026
Q1 		$12.3K Sell
4,410
-1,603
-27% -$4.88K ﹤0.01% 3797
2025
Q4 		$25K Buy
+6,013
New +$31.7K ﹤0.01% 2929
2025
Q3 		– Sell
-4,819
Closed -$10.2K – 5354
2025
Q2 		$10.2K Sell
4,819
-1,809
-27% -$2.71K ﹤0.01% 3958
2025
Q1 		$8.09K Sell
6,628
-995
-13% -$1.4K ﹤0.01% 3918
2024
Q4 		$9.83K Buy
7,623
+4,358
+133% +$10.4K ﹤0.01% 3871
2024
Q3 		$8.98K Sell
3,265
-1,163
-26% -$2.86K ﹤0.01% 3915
2024
Q2 		$10K Sell
4,428
-1,191
-21% -$3.62K ﹤0.01% 4186
2024
Q1 		$13.4K Sell
5,619
-1,748
-24% -$3.31K ﹤0.01% 3395
2023
Q4 		$12.2K Sell
7,367
-6,089
-45% -$11.8K ﹤0.01% 4063
2023
Q3 		$25.8K Buy
13,456
+4,781
+55% +$7.87K ﹤0.01% 3146
2023
Q2 		$12.5K Buy
8,675
+2,456
+39% +$4.17K ﹤0.01% 3863
2023
Q1 		$13K Sell
6,219
-5,902
-49% -$9.53K ﹤0.01% 3967
2022
Q4 		$14K Buy
12,121
+4,740
+64% +$6.31K ﹤0.01% 3504
2022
Q3 		$12K Buy
7,381
+231
+3% +$432 ﹤0.01% 4339
2022
Q2 		$9K Buy
7,150
+4,703
+192% +$6.76K ﹤0.01% 4553
2022
Q1 		$4K Sell
2,447
-6,940
-74% -$13.4K ﹤0.01% 5202
2021
Q4 		$19K Buy
9,387
+6,314
+205% +$18K ﹤0.01% 3718
2021
Q3 		$12K Sell
3,073
-7,129
-70% -$24.2K ﹤0.01% 4145
2021
Q2 		$33K Buy
10,202
+5,138
+101% +$18.3K ﹤0.01% 3386
2021
Q1 		$11K Sell
5,064
-11,611
-70% -$26K ﹤0.01% 4306
2020
Q4 		$37K Sell
16,675
-26,191
-61% -$68.7K ﹤0.01% 3391
2020
Q3 		$114K Buy
42,866
+34,304
+401% +$96.1K ﹤0.01% 3057
2020
Q2 		$26K Buy
8,562
+6,423
+300% +$16.2K ﹤0.01% 3534
2020
Q1 		$4K Buy
+2,139
New +$5.21K ﹤0.01% 2359
2019
Q4 		– Sell
-978
Closed -$4K – 3811
2019
Q3 		$4K Sell
978
-3,055
-76% -$11K ﹤0.01% 3409
2019
Q2 		$17K Sell
4,033
-3,551
-47% -$15.4K ﹤0.01% 2270
2019
Q1 		$39K Buy
+7,584
New +$36.4K ﹤0.01% 1892
2018
Q4 		– Sell
-8,434
Closed -$51K – 3998
2018
Q3 		$51K Buy
8,434
+7,340
+671% +$40.4K ﹤0.01% 1744
2018
Q2 		$7K Buy
+1,094
New +$5.33K ﹤0.01% 2942
2016
Q2 		– Sell
-60
Closed – – 4613
2016
Q1 		$0 Sell
60
-8,812
-99% -$11.8K ﹤0.01% 4403
2015
Q4 		$15K Buy
8,872
+8,538
+2,556% +$19.6K ﹤0.01% 1607
2015
Q3 		$1K Sell
334
-439
-57% -$1.03K ﹤0.01% 3611
2015
Q2 		$3K Sell
773
-201
-21% -$606 ﹤0.01% 3544
2015
Q1 		$3K Sell
974
-7,269
-88% -$26K ﹤0.01% 3559
2014
Q4 		$28K Buy
8,243
+1,180
+17% +$5.21K ﹤0.01% 1375
2014
Q3 		$36K Sell
7,063
-7,543
-52% -$58.7K ﹤0.01% 1816
2014
Q2 		$201K Buy
14,606
+14,506
+14,506% +$181K 0.03% 590
2014
Q1 		$2K Sell
100
-3,654
-97% -$52K ﹤0.01% 3856
2013
Q4 		$30K Sell
3,754
-1,069
-22% -$9.87K 0.01% 1881
2013
Q3 		$48K Buy
+4,823
New +$32.5K 0.01% 1947

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tower Research Capital (TRC)'s GALT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Galectin Therapeutics (GALT) stake by 4.4% in Q2 2026, buying an estimated $505 and bringing the position to 4,605 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Tower Research Capital (TRC) first reported a position in GALT in Q3 2013 and has held it in 41 quarters since. The position peaked at $201K in Q2 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Tower Research Capital (TRC) held 4,605 shares of Galectin Therapeutics worth $21.4K as of Q2 2026.
  • Tower Research Capital (TRC) bought 195 Galectin Therapeutics shares in Q2 2026, an estimated $505.
  • Galectin Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3487 holding.
  • Tower Research Capital (TRC) first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 41 quarters since.
  • Tower Research Capital (TRC)'s Galectin Therapeutics position peaked at $201K in Q2 2014.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.